Evidence map›Paper›PMID 24735919›Full record

ArticleCancer cell2014

Genomic dark matter sheds light on EVI1-driven leukemia.

Richard P Koche, Scott A Armstrong

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Richard P KocheHuman Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Scott A ArmstrongHuman Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: armstros@mskcc.org.

Funding

Targeting to Epigenetic Modications in ALLR01CA176745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ARMSTRONG, SCOTT A, QI, JUN · 2012 to 2022
$4.2M
Molecular pathogenesis of MLL-AF4 leukemiasR01CA140575 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ARMSTRONG, SCOTT A · 2010 to 2014
$1.7M
NCI NIH HHS R01 CA140575NCI NIH HHS R01 CA176745
6 · The paper itself

Abstract

The orchestration of transcriptional programs depends on proper gene-enhancer pairing. While much remains to be learned about this process in normal development, two recent studies in Cell (Gröschel and colleagues) and this issue of Cancer Cell (Yamazaki and colleagues) highlight how the genomic rearrangement of an enhancer plays a causal role in the onset of a leukemogenic program.

Indexed as

Chromosome InversionChromosomes, Human, Pair 3Enhancer Elements, GeneticGene Expression Regulation, NeoplasticAnimalsDNA-Binding ProteinsGATA2 Transcription FactorHematopoiesisHumansLeukemia, Myeloid, AcuteMDS1 and EVI1 Complex Locus ProteinMyelodysplastic SyndromesProto-OncogenesTranscription FactorsDNA-Binding ProteinsGATA2 protein, humanGATA2 Transcription FactorMDS1 and EVI1 Complex Locus ProteinMECOM protein, humanTranscription Factors

Identifiers

PMID24735919
PMCPMC4046890

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.